MarkTomislavOstermanMD

Gastroenterology • Chesterbrook, PA

Advanced Endoscopic Interventional, Inflammatory Bowel Disease

Associate Professor, Medicine, Perelman School of Medicine

Join to view full profile

Dr. Osterman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Osterman's full profile

Already have an account?

Office
250 King of Prussia Rd
Chesterbrook, PA 19087
Phone+1 800-789-7366

Fax+1 610-902-1544

Education & Training

University of Pennsylvania Health SystemFellowship, Gastroenterology, 2002 - 2005
Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2002
Harvard Medical SchoolClass of 1999

Certifications & Licensure

PA State Medical License 2003 - 2024

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Study of Cimzia for the Treatment of Ulcerative Colitis Start of enrollment: 2010 Dec 01
Completed
Phase 2
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis Start of enrollment: 2012 Feb 01
Completed
Phase 2
Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease Start of enrollment: 2014 Feb 01
Completed

Publications & Presentations

PubMed

4 citations
ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse.
Vipul Jairath, Andres Yarur, Mark T Osterman, Alexandra James, Diane Balma
Clinical Gastroenterology and Hepatology. 2024-05-01
53 citations
Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation.
Mark T. Osterman, Maria Rosario, Karen Lasch, Morris Barocas, Jayson D. Wilbur
Alimentary Pharmacology & Therapeutics. 2019-02-01
100 citations
Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin ...
Frank I. Scott, Ronac Mamtani, Colleen M. Brensinger, Kevin Haynes, Zelma Chiesa-Fuxench
JAMA Dermatology. 2016-02-01

Press Mentions

Corrigendum: 2016 ACG Abstracts-Inflammatory Bowel DiseaseJanuary 10th, 2017